MicroRNAs: Potential Biomarkers of Disease Severity in Chronic Rhinosinusitis with Nasal Polyps

Medicina (Kaunas). 2023 Mar 11;59(3):550. doi: 10.3390/medicina59030550.

Abstract

Background and Objectives: Chronic rhinosinusitis with nasal polyps (CRwNP) has multiple clinical presentations, and predictors of successful treatment are correlated to different parameters. Differentially expressed microRNAs in nasal polyps emerge as possible facilitators of precise endotyping in this disease. We aimed to evaluate the correlation between the clinical parameters of CRSwNP and two different microRNAs. Materials and Methods: The expression of miR-125b and miR-203a-3p in nasal polyps (n = 86) and normal nasal mucosa (n = 20) was determined through microarray analysis. Preoperative workup included CT scan, nasal endoscopy, blood tests, symptoms and depression questionnaires. Results: MiR-125b showed significant overexpression in NP compared to the normal nasal mucosa. miR-125b expression levels were positively and significantly correlated with blood eosinophilia (p = 0.018) and nasal endoscopy score (p = 0.021). Although high CT scores were related to miR-125b overexpression, the correlation did not reach statistical significance. miR-203a-3p was underexpressed in nasal polyps and was significantly underexpressed in CRSwNP patients with environmental allergies. Conclusions: Both miR-125b and miR-203a-3p are potential biomarkers in CRSwNP. miR-125b also correlates with the clinical picture, while miR-203a-3p could help identify an associated allergy.

Keywords: biomarker; chronic rhinosinusitis; endotype; microRNA-125b; microRNA-203a-3p; nasal polyp.

MeSH terms

  • Biomarkers
  • Chronic Disease
  • Humans
  • MicroRNAs* / genetics
  • Nasal Polyps* / complications
  • Nasal Polyps* / genetics
  • Nasal Polyps* / metabolism
  • Patient Acuity
  • Rhinitis* / complications
  • Rhinitis* / genetics
  • Sinusitis* / complications
  • Sinusitis* / genetics

Substances

  • MicroRNAs
  • Biomarkers

Grants and funding

This research was funded by the University of Medicine and Pharmacy ‘Iuliu Hatiganu’, Cluj Napoca, Romania, grant number 1033/1/13.01.2021.